A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Trial details
- Registry ID
- NCT04951219
- Phase
- Phase 3
The FDA approved Resmetirom (MGL-3196) on 14 Mar 2024.
Drug identity checked against registry records
Also recorded as MGL-3196
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)NCT04951219 | MDGL | Phase 3 | Active not recruiting | 2027-03Estimated |
| Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASHNCT07335601 | MDGL | Phase 2 | Recruiting | 2028-08Estimated |
| A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease PatientsNCT04197479 | MDGL | Phase 3 | Completed | 2023-01-06Actual |
| A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)NCT05500222 | MDGL | Phase 3 | Active not recruiting | 2026-12Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2024-03-14Day | Resmetirom | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA217785", "applicant_as_listed_by_fda": "MADRIGAL", "brand_names": ["REZDIFFRA"], "active_ingredients": ["RESMETIROM"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20240314", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |